Turning normal tissue biology from a late-discovered liability into an early part of target evaluation.
Tackling the skepticism that comes with multi-omics initiatives and how to answer, what do we actually do with this data?
On the use of comprehensive tumor proteomics to identify cancer targets and biology hiding beyond DNA and RNA.
Quantify specific proteins with sequence-confirmed accuracy – without the antibody limitations of ELISA.
Directly measuring the layers of functional tumor biology that shape how a tumor behaves and responds to treatment.
Mapping pathway‑level mechanisms & molecular drivers behind signatures observed via high-content imaging.
Uncovering meaningful physiological differences among patients who appear similar by diagnosis or lab values.
On closing the gap between molecular measurement & clinical meaning, rapidly extracting actionable biological signals.
PharmaShots delves into Sapient’s mission to transform multi-omics research through innovation & world-class partnerships.
Sharing analytical strategies to ensure omics datasets generate insights that are both truthful & actionable.
Bridging the gap from large-scale omics data generation to deep characterization of disease & treatment biomarkers.
Why PCA quality assessment workflows are critical to generating credible insights from high-dimensional omics data.
